

APASL STC 2025 Tokyo Program at a Glance **Day 1**



October 2 (Thursday) 2025				
	3F Room 1 "Cosmos Hall"	5F Room 2 "Orion"	6F Room 3 "606"	5F Foyer "Subaru" "Matsu"
08:00	8:00- Registration			
09:00	8:50-9:00 Opening Remarks			
	9:00-9:50 Panel Discussion 1 <i>Definition and Epidemiology of SLD</i>	9:00-9:50 Workshop 1 <i>Therapeutic Diversity and Metabolic Response in SLD</i>	9:00-9:30 Parallel Session 1	
10:00	9:50-11:10 Symposium 1 <i>Recent Advances in the Diagnosis of SLD</i>	9:50-10:40 Workshop 2 <i>Strategies for Managing SLD-Related Hepatocellular Carcinoma</i>	9:30-10:00 Parallel Session 2	Poster Viewing
			10:05-10:35 Parallel Session 3	
11:00			10:35-11:05 Parallel Session 4	
12:00	11:10-11:55 State of the Art Lecture 1 <i>Emerging Therapies for MASH Related Fibrosis</i>			
	12:00-13:00 Luncheon Seminar 1 (Gilead Sciences K.K.)	12:00-13:00 Luncheon Seminar 2 (Boehringer Ingelheim)		
13:00	13:10-14:00 Panel Discussion 2 <i>Multidisciplinary Approach for SLD</i>	13:10-14:00 Workshop 3 <i>The Role of Genetic and Environmental Factors in SLD</i>	13:00-13:30 Parallel Session 5	
14:00	14:00-15:20 Symposium 2 <i>ALD: Emerging Insights and Unresolved Challenges (ISBRA Joint Session)</i>		13:30-14:10 Parallel Session 6	
			14:10-14:50 Parallel Session 7	
15:00		14:20-15:20 Late Breaking Session	14:50-15:20 Parallel Session 8	
16:00	15:40-16:40 Teatime Seminar 1 (Novo Nordisk Pharma Ltd.)	15:40-16:40 Teatime Seminar 2 (AbbVie G.K.)		
17:00	16:40-17:10 Special Lecture 1	16:40-17:30 Workshop 4 <i>Surgical Approaches to SLD</i>	16:40-17:10 Parallel Session 9	
	17:10-17:40 Special Lecture 2		17:10-17:40 Parallel Session 10	
18:00		17:40-18:30 Evening Seminar (Miyarisan Pharmaceutical Co., Ltd.)		17:40-18:40 Poster Session Day 1
19:00	18:45-19:00 Awarding Ceremony 19:00-21:00 Welcome Reception			

APASL STC 2025 Tokyo Program at a Glance **Day 2**



October 3 (Friday) 2025			
	3F Room 1 “Cosmos Hall”	5F Room 2 “Orion”	5F Foyer “Subaru” ”Matsu”
08:00	8:00- 9:00 Morning Seminar 1 (Gilead Sciences K.K.)	8:00- 9:00 Morning Seminar 2 (Nobelpharma Co., Ltd.)	
09:00	9:10-10:30 Symposium 3 <i>Novel Insights in SLD pathogenesis (ISHSR Joint Symposium)</i>	9:10-10:00 Workshop 5 <i>Management of SLD-Related Comorbidities</i>	Poster Viewing
10:00	10:30-11:50 Symposium 4 <i>Frontier of Lipid Metabolism and Autophagy (Southern California Research Center for ALPD and Cirrhosis Joint Session)</i>	10:05-10:55 Workshop 6 <i>Exploring Biomarkers for the Diagnosis of SLD</i>	
11:00		11:00-11:50 Workshop 7 <i>Translational Research in SLD</i>	
12:00	12:00-13:00 Luncheon Seminar 3 (AbbVie G.K.)	12:00-13:00 Luncheon Seminar 4 (Meiji Seika Pharma Co., Ltd)	
13:00	13:10-14:10 Plenary Session	13:10-13:40 Parallel Session 11	13:00-14:00 Poster Session Day 2
14:00		13:40-14:10 Parallel Session 12	
15:00	14:10-14:55 State of the Art Lecture 2 <i>A Rationale Approach to Drug Discovery in MetALD</i>		
16:00	14:55-16:15 Symposium 5 <i>Fibrogenesis in SLD</i>	14:55-16:15 Symposium 6 <i>Practical Management of SLD and Novel Insights</i>	
17:00	16:15-17:35 Symposium 7 <i>Cancer Development in SLD</i>	16:15-16:45 Parallel Session 13	
		16:45-17:35 Workshop 8 <i>The Role of Gut-liver Axis in SLD</i>	
18:00	17:40-17:50 Closing Remarks		

As of Sep 9, 2025

*The program is subject to change.